Complications of peripheral angioplasty access

Original title: Access Site Complications After Peripheral Vascular Interventions. Incidence, Predictors, and Outcomes. Reference: Daniel Ortiz et al. Circ Cardiovasc Interv. 2014 Nov 11. Epub ahead of print.

 

Hematomas and pseudoaneurysms are the most common complications of peripheral angioplasty, though its incidence and risk factors are unclear. A retrospective analysis was performed in 22226 patients receiving peripheral angioplasty between 2007 and 2013 at several centers. The primary end points included the incidence and complication predictors related to vascular access, post procedure length of stay and mortality at 30 days and one year. Access complications occurred in 936 procedures (3.5%). Of these, 74.4% were minor, 9.7% were moderate requiring transfusion, 5.4% were moderate requiring thrombin injection and 10.5% were severe complications requiring surgery.

Predictors of complications related to access were age (>75 years), female gender, access different to femoral, introducer >6 Fr, use of thrombolytics, arterial dissection, fluoroscopy time     >30 minutes, urgent indication and the absence of percutaneous closure devices procedure. In patients who had complications access, hospital stay was significantly higher (1.2 ± 1.6 versus 1.9 ± 1.9 days; p = 0.002) and in which the complication was severe, an increased mortality was observed at 30 days (6.1% versus 1.4%; p <0.001). In those which complication was moderate but requiring transfusion, mortality was higher per year (12.1% versus 5.7%, p <0.001).

Conclusion

Several factors independently predict the risk of complications of vascular access in patients receiving peripheral angioplasty. The appropriate use of anti-thrombotic and vascular closure devices could improve results.

Editorial comment

This issue, which has been widely analyzed in coronary angioplasty, did not have much data for peripheral angioplasty. Two of the most useful resources in coronary angioplasty as radial access and use of bivalirudin, have technical limitations or insufficient evidence in the peripheral angioplasty. The radial access may be useful in selected cases of renal angioplasty, iliac primitive or carotid, but not much further. Bivalirudin has some evidence in carotid angioplasty but not in other territories.

SOLACI

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...